Ir a las Transacciones
Salud

Procaps S.A. has raised funds

Procaps S.A. has closed a club deal bank facility in a transaction financed by Bancolombia S.A. and Banco Davivienda S.A. The funds will be designated for the refinancing of existing debts owed to current creditors. This strategic allocation will empower the company to navigate its growth plan with enhanced financial strength.

Procaps S.A. is a Colombian multinational firm, leader in the pharmaceutical market. The company develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and clinical solutions. Procaps distributes its products to 50 markets.

Oaklins’ team in Chile acted as the exclusive financial advisor to Procaps S.A. in this transaction.

Contáctese con el equipo de la transacción

Sebastián Cereceda

Socio
Santiago, Chile
Oaklins LarrainVial

Antonio Benvenuto

Asociado Director
Santiago, Chile
Oaklins LarrainVial

Transacciones relacionadas

Forza Doors has secured new debt facilities
Servicios de Construcción e Ingeniería

Forza Doors has secured new debt facilities

Forza Doors Ltd. has secured new senior debt facilities from Triple Point. The new debt facilities will be used to refinance the business and support its future growth.

Aprenda más
Sun European Partners has secured financing to support its acquisition of B&H Worldwide
Private Equity | Logística

Sun European Partners has secured financing to support its acquisition of B&H Worldwide

Sun European Partners has raised debt facilities to support its acquisition of B&H Worldwide.

Aprenda más
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Salud

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval

Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.

Aprenda más